UPC Analytics
ENDE
Overview · Filed: —

ACT_3186/2025

INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES

Provisional measuresProvisional MeasuresLisbon LDApplication for provisional measures—
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • Boehringer Ingelheim International GmbH
Reps: Joana Catarina Piriquito Santos; Sara Nazaré; Beatriz Lima

Respondents

  • ZENTIVA PORTUGAL, LDA
Reps: Patrícia Paias
Judges
  • Rute LopesPresiding judge, judge-rapporteur
  • Camille LignièresLegally qualified judge
  • Petri RinkinenLegally qualified judge
Patents
  • EP 1 830 843
CPC codes: C07D403/12, A61K31/4178, A61K31/4045, A61K31/496, A61K31/495, A61K47/38, A61K9/08, C07D209/34, A61K9/1623, A61K47/10, A61K31/404, A61K9/0031…

Sector: Organic Chemistry

Outcome
PI denied
Filed: —
First decided: May 8, 2025
Language: —

Lisbon Local Division denied Boehringer Ingelheim International GmbH's application for a preliminary injunction against Zentiva Portugal, LDA concerning EP 1 830 843 (nintedanib for idiopathic pulmonary fibrosis). The court found no imminent infringement: Zentiva's receipt of marketing authorisations and filing of a parallel exclusivity period (PEP) request did not demonstrate that market entry was imminent before patent expiry. The PEP request was filed in the usual course of business and the Defendant was aware of the risk of PEP expiry. Value of case set at EUR 1,000,000.